\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Alzheimer's Disease}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{Pathology}{section.1.1}% 3
\BOOKMARK [2][-]{subsection.1.1.2}{The two hallmarks: plaques and tangles}{section.1.1}% 4
\BOOKMARK [2][-]{subsection.1.1.3}{Genetic Component}{section.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.4}{Mouse Models}{section.1.1}% 6
\BOOKMARK [2][-]{subsection.1.1.5}{Currently available mouse models in AD}{section.1.1}% 7
\BOOKMARK [1][-]{section.1.2}{Gene expression and regulation}{chapter.1}% 8
\BOOKMARK [1][-]{section.1.3}{Transcriptional profiling}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.3.1}{Alternative Splicing}{section.1.3}% 10
\BOOKMARK [2][-]{subsection.1.3.2}{Short-read RNA-sequencing}{section.1.3}% 11
\BOOKMARK [2][-]{subsection.1.3.3}{Long-read sequencing approaches}{section.1.3}% 12
\BOOKMARK [2][-]{subsection.1.3.4}{Hybrid approach of short and long read sequencing}{section.1.3}% 13
\BOOKMARK [2][-]{subsection.1.3.5}{Isoform quantification}{section.1.3}% 14
\BOOKMARK [1][-]{section.1.4}{Aims and Objectives}{chapter.1}% 15
\BOOKMARK [1][-]{section.1.5}{Future Directions}{chapter.1}% 16
\BOOKMARK [0][-]{chapter.2}{Long-read Sequencing}{}% 17
\BOOKMARK [1][-]{section.2.1}{Pacific Biosciences: Isoform Sequencing}{chapter.2}% 18
\BOOKMARK [2][-]{subsection.2.1.1}{Introduction}{section.2.1}% 19
\BOOKMARK [2][-]{subsection.2.1.2}{Lab Pipeline}{section.2.1}% 20
\BOOKMARK [2][-]{subsection.2.1.3}{Bioinformatics Pipeline}{section.2.1}% 21
\BOOKMARK [1][-]{section.2.2}{Iso-Seq: Optimisation}{chapter.2}% 22
\BOOKMARK [2][-]{subsection.2.2.1}{Varying CCS parameters}{section.2.2}% 23
\BOOKMARK [2][-]{subsection.2.2.2}{Additional parameters}{section.2.2}% 24
\BOOKMARK [1][-]{section.2.3}{Oxford Nanopore: cDNA Sequencing}{chapter.2}% 25
\BOOKMARK [2][-]{subsection.2.3.1}{Introduction}{section.2.3}% 26
\BOOKMARK [2][-]{subsection.2.3.2}{Lab Pipeline}{section.2.3}% 27
\BOOKMARK [2][-]{subsection.2.3.3}{Bioinformatics Pipeline}{section.2.3}% 28
\BOOKMARK [0][-]{chapter.3}{Whole Transcriptome}{}% 29
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 30
\BOOKMARK [2][-]{subsection.3.1.1}{Mouse model of AD amyloidopathy: J20}{section.3.1}% 31
\BOOKMARK [2][-]{subsection.3.1.2}{Mouse model of AD tauopathy: rTg4510}{section.3.1}% 32
\BOOKMARK [1][-]{section.3.2}{Methods}{chapter.3}% 33
\BOOKMARK [2][-]{subsection.3.2.1}{RNA Extraction}{section.3.2}% 34
\BOOKMARK [2][-]{subsection.3.2.2}{RNA-Seq Library Preparation, Illumina Sequencing \046 raw data processing}{section.3.2}% 35
\BOOKMARK [2][-]{subsection.3.2.3}{Iso-Seq Library Preparation}{section.3.2}% 36
\BOOKMARK [2][-]{subsection.3.2.4}{ONT Library Preparation}{section.3.2}% 37
\BOOKMARK [2][-]{subsection.3.2.5}{Iso-Seq Data Processing}{section.3.2}% 38
\BOOKMARK [2][-]{subsection.3.2.6}{ONT Data Processing}{section.3.2}% 39
\BOOKMARK [2][-]{subsection.3.2.7}{Characterisation of Alternative Splicing Events}{section.3.2}% 40
\BOOKMARK [1][-]{section.3.3}{Results}{chapter.3}% 41
\BOOKMARK [2][-]{subsection.3.3.1}{PacBio's Iso-Seq run performance and sequencing metrics}{section.3.3}% 42
\BOOKMARK [2][-]{subsection.3.3.2}{Nanopore Sequencing run performance and sequencing metrics}{section.3.3}% 43
\BOOKMARK [2][-]{subsection.3.3.3}{Transcriptome annotation}{section.3.3}% 44
\BOOKMARK [2][-]{subsection.3.3.4}{Isoform diversity}{section.3.3}% 45
\BOOKMARK [2][-]{subsection.3.3.5}{Iso-Seq vs RNA-Seq}{section.3.3}% 46
\BOOKMARK [2][-]{subsection.3.3.6}{Novel isoforms}{section.3.3}% 47
\BOOKMARK [2][-]{subsection.3.3.7}{Intron Retention and Nonsense mediated decay}{section.3.3}% 48
\BOOKMARK [2][-]{subsection.3.3.8}{Fusion Genes}{section.3.3}% 49
\BOOKMARK [2][-]{subsection.3.3.9}{LncRNA}{section.3.3}% 50
\BOOKMARK [2][-]{subsection.3.3.10}{Novel Genes}{section.3.3}% 51
\BOOKMARK [1][-]{section.3.4}{Discussion}{chapter.3}% 52
\BOOKMARK [0][-]{chapter.4}{Targeted Transcriptome}{}% 53
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 54
\BOOKMARK [1][-]{section.4.2}{Methods}{chapter.4}% 55
\BOOKMARK [1][-]{section.4.3}{Results}{chapter.4}% 56
\BOOKMARK [2][-]{subsection.4.3.1}{Run performance and sequencing metrics}{section.4.3}% 57
\BOOKMARK [2][-]{subsection.4.3.2}{Transcriptome annotation}{section.4.3}% 58
\BOOKMARK [2][-]{subsection.4.3.3}{Comparison with whole transcriptome}{section.4.3}% 59
\BOOKMARK [0][-]{chapter.5}{Transcriptional differences between WT and TG mice}{}% 60
\BOOKMARK [1][-]{section.5.1}{Introduction}{chapter.5}% 61
\BOOKMARK [1][-]{section.5.2}{Methods}{chapter.5}% 62
\BOOKMARK [2][-]{subsection.5.2.1}{Iso-Seq Processing and Isoform Quantification}{section.5.2}% 63
\BOOKMARK [2][-]{subsection.5.2.2}{Quantification of human MAPT transgene expression}{section.5.2}% 64
\BOOKMARK [2][-]{subsection.5.2.3}{Characterisation of Alternative Splicing Events}{section.5.2}% 65
\BOOKMARK [2][-]{subsection.5.2.4}{Differential expression analysis}{section.5.2}% 66
\BOOKMARK [1][-]{section.5.3}{Results}{chapter.5}% 67
\BOOKMARK [2][-]{subsection.5.3.1}{Change in endogeneous expression}{section.5.3}% 68
\BOOKMARK [2][-]{subsection.5.3.2}{Transcriptome Annotation}{section.5.3}% 69
\BOOKMARK [2][-]{subsection.5.3.3}{Alternative Splicing}{section.5.3}% 70
\BOOKMARK [2][-]{subsection.5.3.4}{Differential Gene Expression Analysis}{section.5.3}% 71
\BOOKMARK [2][-]{subsection.5.3.5}{Differential Isoform Expression Analysis}{section.5.3}% 72
\BOOKMARK [2][-]{subsection.5.3.6}{Differential Isoform Usage Analysis}{section.5.3}% 73
\BOOKMARK [2][-]{subsection.5.3.7}{Differential Feature Inclusion Analysis}{section.5.3}% 74
\BOOKMARK [0][-]{chapter.6}{BDR}{}% 75
\BOOKMARK [0][-]{chapter.7}{Conclusion}{}% 76
\BOOKMARK [-1][-]{part.1}{ Appendix}{}% 77
\BOOKMARK [0][-]{chapter.1}{Iso-Seq Targeted and Whole Transcriptome Protocol}{part.1}% 78
\BOOKMARK [1][-]{subsection.1.0.1}{Requirement of Sample quality}{chapter.1}% 79
\BOOKMARK [2][-]{subsection.1.0.2}{General}{subsection.1.0.1}% 80
\BOOKMARK [2][-]{subsection.1.0.3}{First Strand Synthesis}{subsection.1.0.1}% 81
\BOOKMARK [2][-]{subsection.1.0.4}{PCR Cycle Optimisation}{subsection.1.0.1}% 82
\BOOKMARK [2][-]{subsection.1.0.5}{Large-Scale PCR}{subsection.1.0.1}% 83
\BOOKMARK [2][-]{subsection.1.0.6}{Bead Purification of Large-Scale PCR Products}{subsection.1.0.1}% 84
\BOOKMARK [2][-]{subsection.1.0.7}{Pooling Fraction 1 \(1X\) and 2 \(0.40X\)}{subsection.1.0.1}% 85
\BOOKMARK [2][-]{subsection.1.0.8}{Target Capture using IDT probes}{subsection.1.0.1}% 86
\BOOKMARK [2][-]{subsection.1.0.9}{SMRTbell Template Preparation}{subsection.1.0.1}% 87
\BOOKMARK [0][-]{chapter.2}{Oxford Nanopore Transcriptome Protocol}{part.1}% 88
\BOOKMARK [1][-]{subsection.2.0.1}{cDNA Synthesis and Amplification}{chapter.2}% 89
\BOOKMARK [2][-]{subsection.2.0.2}{Bead Purification of Large Scale PCR Products}{subsection.2.0.1}% 90
\BOOKMARK [2][-]{subsection.2.0.3}{ONT MinION Library Preparation}{subsection.2.0.1}% 91
\BOOKMARK [2][-]{subsection.2.0.4}{Priming the Flow Cell}{subsection.2.0.1}% 92
\BOOKMARK [2][-]{subsection.2.0.5}{Library loading into the Flow Cell}{subsection.2.0.1}% 93
\BOOKMARK [0][-]{chapter.3}{cDNA Synthesis alternative approach}{part.1}% 94
